
|Videos|January 29, 2018
A Dose-Escalation Study of Regorafenib in mCRC
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses a randomized phase II trial to evaluate dosing strategies for regorafenib (Stivarga) in patients with refractory metastatic colorectal cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
5


































